RIM
HZNP

Regent Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Regent Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$11.5M Sell
101,451
-2,034
-2% -$169K 3.09% 5
2022
Q3 		$6.41M Sell
103,485
-1,690
-2% -$118K 1.87% 11
2022
Q2 		$8.39M Buy
105,175
+805
+0.8% +$76.2K 2.34% 7
2022
Q1 		$11M Buy
104,370
+307
+0.3% +$29.9K 2.54% 8
2021
Q4 		$11.2M Buy
104,063
+29
+0% +$3.16K 2.44% 8
2021
Q3 		$11.4M Sell
104,034
-5,765
-5% -$598K 2.73% 7
2021
Q2 		$10.3M Sell
109,799
-3,210
-3% -$295K 2.41% 8
2021
Q1 		$10.4M Buy
113,009
+514
+0.5% +$43.4K 2.62% 9
2020
Q4 		$8.23M Sell
112,495
-5,532
-5% -$411K 2.28% 9
2020
Q3 		$9.17M Sell
118,027
-6,666
-5% -$459K 2.83% 8
2020
Q2 		$6.93M Sell
124,693
-7,045
-5% -$301K 2.3% 9
2020
Q1 		$3.9M Sell
131,738
-810
-0.6% -$27.4K 1.61% 16
2019
Q4 		$4.8M Buy
132,548
+2,213
+2% +$67.9K 1.47% 18
2019
Q3 		$3.55M Buy
130,335
+1,225
+0.9% +$31.7K 1.16% 22
2019
Q2 		$3.11M Buy
129,110
+38,960
+43% +$988K 1.01% 29
2019
Q1 		$2.38M Buy
90,150
+37,660
+72% +$892K 0.79% 38
2018
Q4 		$1.03M Buy
52,490
+8,000
+18% +$157K 0.38% 76
2018
Q3 		$871K Buy
44,490
+7,400
+20% +$141K 0.27% 97
2018
Q2 		$614K Sell
37,090
-1,300
-3% -$19.8K 0.21% 112
2018
Q1 		$545K Buy
+38,390
New +$567K 0.18% 122

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Regent Investment Management's HZNP Position: Q4 2022 in Review

Regent Investment Management reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 2% in Q4 2022, selling an estimated $169K and leaving 101,451 shares worth $11.5M. The position accounts for 3.09% of the portfolio, ranked #5.

Regent Investment Management first reported a position in HZNP in Q1 2018 and has held it in 20 quarters since. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

  • Regent Investment Management held 101,451 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $11.5M as of Q4 2022.
  • Regent Investment Management sold 2,034 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $169K.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 3.09% of Regent Investment Management's portfolio in Q4 2022, its #5 holding.
  • Regent Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2018 and has held it in 20 quarters since.
  • 615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Regent Investment Management's 13F filing for Q4 2022, filed 26 Jan 2023.